Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

The report provides a comprehensive analysis of the genome editing market, focusing on technologies like CRISPR-Cas, TALEN, ...

Katy Rezvani, MD, PhD, discusses advancements in CAR-NK cell therapy, focusing on enhancing antitumor efficacy while ensuring safety through precise gene editing techniques.

MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemiaOral presentation highlights safe, robust, and durable reduction of apoC-III and ...

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

REPAIRome specifically addresses the repair of one of the most serious types of DNA damage, DNA double-strand breaks (DSBs).

The clinical success of CRISPR-based treatments is fundamentally dependent on sophisticated gRNA targeting systems that ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, ...